NEW YORK, Oct. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

World Pain Relieving Drug Market 2012-2022

http://www.reportlinker.com/p0572964/World-Pain-Relieving-Drug-Market-20...

Report Details

New study reveals sales potential of this large, expanding market

See what the future holds for painkillers. Visiongain's report gives you revenue predictions to 2022. You find data, trends, opportunities and commercial prospects.

That new study lets you assess forecasted sales at overall world market, submarket, product and national level. You see why the pain relievers industry and market will grow, as we predict. 

In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, R&D and commercial developments. You receive 79 tables, 74 charts and two research interviews.

The following sections highlight what you discover in the report.

Prospects for submarkets and products

In addition to analyses of the overall world market, you see revenue forecasting of five world-level submarkets to 2022: 

• Narcotics

• Non-narcotics

• Neuropathic pain relievers

• Treatments for migraines

• Treatments for arthritis.

Also, you see how 28 leading drugs - including Oxycontin ER, Panadol, Lyrica and Zomig - can perform to 2022. Our study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines. There, you find revenue forecasts and other data.

The work also breaks the overall world market into leading national markets.

Prospects for leading countries shown to 2022

Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for pain-treating products. 

You discover revenue forecasts to 2022 for nine national markets:

• US

• Japan

• Germany, France, UK, Italy and Spain (EU5 nations)

• India and China.

This decade, revenues from India and China will be among the fastest growing worldwide. In particular, product launches from 2012 onwards will benefit regional and national markets.

Research and development activities

What's happening in the R&D pipeline for painkillers? You see developmental trends there:

• Narcotic drugs

• Non-narcotic products

• Neuropathic treatments

• Anti-migraine agents

• Arthritic pain relievers.

Discover how technological progress changes the sector. Our investigation explains, bringing together many issues.

Prominent issues affecting the pain treatment sector

Our study lets you assess industry trends and outlooks worldwide from 2012. As the work shows, many issues affect the industry and market:

• Better treatment of acute and chronic pain worldwide, including cancer pain

• Anticonvulsants, analgesics, COX-2 inhibitors, novel opioids, cannabinoids and local anaesthetics

• Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and aldose reductase inhibitors

• Disease modifying anti-rheumatic drugs (DMARDs)

• Biologics (e.g. monoclonal antibodies, MAbs) for rheumatoid arthritis (RA)

• Reimbursement, regulations, patent expiries, generic competition and OTC switching.

You see discussions of technological, commercial and economic matters, with emphasis on organisations competing in the industry. 

Discussions of leading companies and prospects for market growth 

What will happen next? The pharmaceutical industry will improve treatments for pain relief and increase revenues there from 2012 to 2022. The R&D pipeline is strong. 

Overall world revenue for that market area will reach $61.6bn in 2012, our report forecasts. Ageing populations and diseases such as cancer, arthritis and diabetes will increase sales of painkillers. Also, improved drug delivery and new formulations will be important. 

You find discussions of Pfizer, GSK, Johnson & Johnson, Bristol-Myers Squibb and other developers and manufacturers. Also, you see our interviews with two companies. This decade, many opportunities will arise.

Eight ways World Pain Relieving Drug Market 2012-2022benefits you

In particular, then, our study gives you the following knowledge on painkilling drugs:

• Forecasted revenues to 2022 for the overall world market and submarkets

• Potential revenues of 28 leading products to 2022

• Market forecasting to 2022 for the US, Japan, leading EU countries (Germany, France, the UK, Italy and Spain), Indiaand China

• Assessment of companies - discussions of activities and outlooks

• Review of R&D pipelines by treatment area - progress and trends

• Opinions on the sector, including our research interviews with leaders in industry

• Investigation of competition and opportunities influencing sales

• Discussion of what stimulates and restrains the industry and market.

That work gives independent analyses from our primary and secondary research. You receive information found only in our report. 

With our study, you find business intelligence to help you understand the future of that industry and market. 

Ordering now lets you discover prospects for drugs treating pain

Visiongain's study is for everybody needing commercial analyses for the treatment of pain. You find data, trends and predictions there. Please order that report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6 

Table of Contents

1.      Executive Summary

1.1 The Pain Relieving Drug Market: Overview

1.2 Aims, Scope and Format of the Report

1.3 Research and Analysis Methods

2. Introduction to the Pain Relieving Drug Market

2.1 What is Pain?

2.1.1 Historical Aspects of Pain

2.2 Pain Pathways and the Origin of Pain

2.2.1 WHO Pain Ladder

2.3 Classification and Types of Pain

2.3.1 Acute Pain

2.3.2 Chronic Pain

2.3.3 Psychosocial Effects of Chronic Pain

2.3.4 Chronic Cancer Pain

2.3.5 Breakthrough Cancer Pain

2.4 Neuropathic Pain

2.4.1 Distinguishing Neuropathic Pain

2.5 Neurochemistry of Pain

2.5.1 Prostaglandins

2.5.2 Opioids

2.6 Treatment

2.6.1 Opioids in the Treatment of Pain

2.7 OTC Pain Relievers

3. The World Pain Relieving Drug Market, 2012-2022

3.1 The World Pain Relieving Drug Market: Analysis and Forecast, 2012-2022

3.2 Submarket Categories of the World Pain Drug Market

3.2.1 Anti-Arthritic Drug Sales Will Continue to Dominate

3.2.2 Neuropathic Pain Market Will Grow

3.3 Success in the World Pain Treatment Market Has Been Challenging

3.4 The Pain Relieving Drug Market Will Expand

4. Narcotic Pain Relieving Drugs: World Market Analysis and Forecast, 2012-2022

4.1 Oxycontin ER (Purdue Pharma): Market Analysis and Forecast, 2012-2022

4.1.1 Launch of Tamper Resistant Oxycontin ER

4.1.2 Patent and Legal Battles of Oxycontin ER

4.1.3 Oxycontin ER Sales Forecast, 2012-2022

4.2 Duragesic (Johnson & Johnson): Market Analysis and Forecast, 2012-2022

4.2.1 Duragesic Sales Forecast, 2012-2022

4.3 Opana ER (Endo Pharmaceuticals): Market Analysis and Forecast, 2012-2022

4.3.1 Development of Tamper Resistant Opana ER

4.3.2 Opana ER Sales Forecast, 2012-2022

4.4 Ultram (Johnson & Johnson, Ortho-McNeil): Market Analysis and Forecast, 2012-2022

4.5 World Market Forecast for Other Narcotic Drugs, 2012-2022

5. Non-Narcotic Pain Relieving Drugs: World Market Analysis and Forecast, 2012-2022

5.1 Advil (Pfizer): Market Analysis and Forecast, 2012-2022

5.1.1 Development of Advil (Ibuprofen)

5.1.2 Advil Sales Forecast, 2012-2022

5.2 Panadol (GSK): Market Analysis and Forecast, 2012-2022

5.2.1 Panadol Sales Forecast, 2012-2022

5.3 Bayer Aspirin (Bayer): Market Analysis and Forecast, 2012-2022

5.3.1 Development of Bayer Aspirin (Acetylsalicyclic Acid)

5.3.2 Bayer Aspirin Sales Forecast, 2012-2022

5.4 Efferalgan (Bristol-Myers Squibb): Market Analysis and Forecast, 2012-2022

5.5 Tylenol (Johnson & Johnson, Ortho-McNeil): Market Analysis and Forecast, 2012-2022

5.5.1 Eroded Sales in 2011

5.5.2 Tylenol Sales Forecast, 2012-2022

5.6 Other Non-Narcotic Pain Relieving Drugs: Market Analysis and Forecast, 2012-2022

6. Neuropathic Pain Relieving Drugs: World Market Analysis and Forecast, 2012-2022

6.1 Treatment Options

6.2 Pharmacological Treatments

6.2.1 Anti-Convulsants

6.2.2 Analgesics

6.2.3 Local Anaesthetics

6.2.4 Anti-Depressants

6.2.5 Aldose Reductase Inhibitors

6.3 World Neuropathic Pain Relieving Drug Sales Forecast, 2012-2022

6.4 Lyrica (Pfizer): Market Analysis and Forecast, 2012-2022

6.4.1 Impact of Lyrica Patent Expiry

6.5 Cymbalta (Eli Lilly): Market Analysis and Forecast, 2012-2022

6.6 Lidoderm (Endo Pharmaceuticals): World Market Analysis and Forecast, 2012-2022

6.6.1 Impact of Lidoderm Patent Expiry

6.7 Neurontin Market Forecast, 2012-2022

6.8 Nucynta ER (Grünenthal GmbH, Johnson & Johnson): Market Analysis and Forecast, 2012-2022

6.8.1 Development of Nucynta ER (Tapentadol)

6.8.2 Nucynta ER Sales Forecast, 2012-2022

6.8.3 Nucynta ER Has High Potential

6.9 Qutenza (NeurogesX) and NGX-1998 Market Prospects

6.10 Kinedak (Ono Pharmaceutical) Market Prospects

6.11 Development and Market Prospects of Horizant (Xenoport, GSK)

6.12 Will Gralise (Depomed) Become a Market Leader?

6.13 Future Treatment of Neuropathies

6.13.1 Therapies That Can Target the Underlying Cause Are in Demand

7. Anti-Migraine Drugs: World Market Analysis and Forecast, 2012-2022

7.1 How is Migraine Treated and Prevented?

7.1.1 Migraine Treatment

7.1.2 Migraine Prevention

7.2 World Anti-Migraine Drug Sales Forecast, 2012-2022

7.3 Maxalt (Merck & Co.): Market Analysis and Forecast, 2012-2022

7.4 Zomig (AstraZeneca): Market Analysis and Forecast, 2012-2022

7.5 Relpax (Pfizer): Market Analysis and Forecast, 2012-2022

7.6 Imitrex/Imigran (GSK): Market Analysis and Forecast, 2012-2022

7.7 Botox (Allergan): Market Analysis and Forecast, 2012-2022

7.7.1 Botox Will Boost World Migraine Sales

7.8 Axert (Johnson & Johnson, Almirall): Market Analysis and Forecast, 2012-2022

7.9 Treximet (GSK, Pozen): Market Analysis and Forecast, 2012-2022

7.10 What Does the Future Hold for Migraine Therapy?

7.11 Unmet Needs in the Treatment of Migraine

8. Anti-Arthritic Pain Drugs: World Market Analysis and Forecast, 2012-2022

8.1 Arthritis

8.2 What Drugs are Used to Treat Arthritis?

8.2.1 Pain Relieving Drugs and Analgesics

8.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

8.2.3 Corticosteroids

8.2.4 Disease Modifying Anti-Rheumatic Drugs (DMARDs)

8.2.5 Biologics

8.3 Biologics for Rheumatoid Arthritis Treatment

8.3.1 Side Effects of Biologics

8.4 World Anti-Arthritic Pain Drug Sales Forecast, 2012-2022

8.5 Humira (Abbott Laboratories): Market Analysis and Forecast, 2012-2022

8.5.1 Long-Term Prospects for Humira

8.6 Enbrel (Amgen, Pfizer, Takeda): Market Analysis and Forecast, 2012-2022

8.6.1 Amgen Continues to Benefit from Enbrel Sales

8.6.2 Enbrel Sales Will Show an Initial Increase

8.6.3 Study Eases Fears of TNF Blocker Cancer Risk

8.6.4 New Enbrel Delivery System

8.6.5 Sales of Enbrel will Eventually Decline

8.6.6 Enbrel Faces Competition from Several Other Biotech Drugs

8.7 Remicade (Johnson & Johnson): Market Analysis and Forecast, 2012-2022

8.7.1 Long Term Prospects for Remicade

8.8 Rituxan (MabThera-Roche, Biogen Idec): Market Analysis and Forecast, 2012-2022

8.8.1 Rituxan is a Leading Biosimilar Target

8.9 Celebrex (Pfizer): Market Analysis and Forecast, 2012-2022

8.9.1 Development of Celebrex

8.9.2 Celebrex Sales Forecast, 2012-2022

8.10 Voltaren (Endo Pharmaceuticals, Novartis): Market Analysis and Forecast, 2012-2022

8.10.1 Voltaren Sales Forecast, 2012-2022

8.11 Arcoxia (Merck & Co.): Market Analysis and Forecast, 2012-2022

8.11.1 Development of Arcoxia

8.11.2 Arcoxia Sales Forecast, 2012-2022

8.12 Outlook for the Anti-Arthritic Pain Drug Market

9. Drivers and Restraints in the Worldwide Pain Relieving Drug Market, 2012-2022

9.1 SWOT Analysis of the World Pain Relieving Drug Market, 2012-2022

9.2 Market Drivers

9.3 Market Restraints

9.4 The Pain Market After the Withdrawal of COX-2 Inhibitors

9.5 Lack of Adequate Reimbursement Limits Potential of Pain Drugs

9.6 Reformulations of Existing Drugs Will DriveMarket Growth

9.7 Narcotics Market Will Continue to Grow Despite Reported Concerns of Side Effects

9.8 Risk of Intestinal Bleeding Associated With Use of NSAIDs

9.9 Ageing Population

9.10 Patent Expiries Will Lead to Generic Competition

9.11 OTC Switching

9.12 Education in Pain Management is a Key Unmet Need

9.12.1 Personalised Pain Management Therapy

10. Leading National Markets for Pain Relieving Drugs, 2012-2022

10.1 The Pain Relieving Drug Market: Regional Sales Breakdown

10.2 Pain Drug Revenues in Leading National Markets, 2012-2022

10.2.1 The Pain Relieving Drug Market in the US, 2012-2022

10.2.2 The Pain Relieving Drug Market in Japan, 2012-2022

10.2.3 Top 5 EU Markets for Pain Relieving Drugs, 2012-2022

10.2.4 The Pain Relieving Drug Market in Germany, 2012-2022

10.2.5 The Pain Relieving Drug Market in France, 2012-2022

10.2.6 The Pain Relieving Drug Market in the UK, 2012-2022

10.2.7 The Pain Relieving Drug Market in Italy, 2012-2022

10.2.8 The Pain Relieving Drug Market in Spain, 2012-2022

10.3 Emerging Economies: India and China, 2012-2022

10.3.1 The Pain Relieving Drug Market in China, 2012-2022

10.3.2 The Pain Relieving Drug Market in India, 2012-2022

10.4 The Pain Relieving Drug Market in the Rest of the World, 2012-2022

11. The R&D Pipeline for the Treatment of Pain, 2012

11.1 The R&D Pipeline for Pain Drugs is Large and Expanding

11.2 The Potential of the Pain Market Has Encouraged R&D

11.3 Innovation Rules for Early Stage Pipeline Drugs

11.4 Narcotic Pain Relieving Drug Pipeline, 2012

11.4.1 Acurox (Acura, Pfizer)

11.4.2 Remoxy (King Pharmaceuticals, Pfizer, Pain Therapeutics, Durect)

11.4.3 BEMA Buprenorphine (BioDelivery Sciences, Endo Pharmaceuticals)

11.4.4 Morphine Glucuronide (Paion)

11.4.5 MoxDuo IR (Shire; China Aoxing; QRxPharma)

11.4.6 Acuracet (Pfizer, Acura)

11.4.7 ARX 02 (AcelRx Pharmaceuticals)

11.4.8 Zohydro (Zogenix)

11.4.9 COL-003 (Collegium)

11.4.10 ALO 02 (Pfizer)

11.4.11 Subsys (Insys Therapeutics)

11.4.12 Oxceta (Pfizer, Acura)

11.5 Non-Narcotic Pain Relieving Drug Pipeline, 2012

11.5.1 Exparel (Pacira Pharmaceuticals)

11.5.2 Lofexidine HCl (US WorldMeds) 

11.5.3 Synera (Nuvo Research)

11.5.4 Neosaxitoxin (Proteus SA)

11.5.5 Adlea (ALGRX-4975) (Anesiva, Johns HopkinsUniversity)

11.5.6 OMS 103 HP (Omeros)

11.5.7 Tetrodotoxin (WEX, CK Life Sciences)

11.5.8 CE 224535 (Pfizer)

11.5.9 MK-2295 (Ligand, Merck & Co.)

11.6 Neuropathic Pain Relieving Drug Pipeline, 2012

11.6.1 Retigabine (Valeant, GSK)

11.6.2 Perampanel (Eisai)

11.6.3 Serenbotase (Syntaxin, Allergan)

11.6.4 EMA401 (Spinifex)

11.6.5 KRN5500 (Dara Biosciences)

11.6.6 NT-11624 (Neurotune)

11.6.7 ARC-2022 (Arcion)

11.6.8 ARC-4558 (Arcion)

11.6.9 Amiket (EpiCept)

11.6.10 Ralfinamide (Newron)

11.6.11 Eladur (Durect)

11.6.12 AVP-923 (Avanir Pharmaceuticals) 

11.7 Anti-Migraine Drug Pipeline, 2012

11.7.1 Lavadex (MAP Pharmaceuticals)

11.7.2 Zelrix (NuPathe)

11.7.3 BMS-927711 (Bristol-Myers Squibb)

11.7.4 Lasmiditan (CoLucid Pharmaceuticals)

11.7.5 Telcagepant (Merck & Co.)

11.7.6 NXN-188 (NeurAxon)

11.7.7 BGG492 (Novartis)

11.7.8 LY2300559 (Eli Lilly)

11.8 Anti-Arthritic Pain Drug Pipeline, 2012

11.8.1 Duexa (Horizon Pharma)

11.8.2 Ibuprofen-PC (PLx Pharma)

11.8.3 Naproxidnod (NicOx)

11.8.4 Lodotra (Horizon; SkyePharma)

11.8.5 Fostamatinib (Rigel Pharmaceuticals, AstraZeneca)

11.8.6 Tofacitinib (Pfizer)

11.8.7 Ofatumumab (Genmab, GSK)

11.8.8 Mastinitib (AB Science)

11.8.9 Belimumab (GSK, Human Genome Sciences)

11.9 The Future of Pain Research

11.9.1 Advanced Drug Delivery

11.9.1.1 Delivery of Low Solubility Drugs

11.9.2 Challenges Faced by Novel Painkillers - Monoclonal Antibodies (MAbs)

11.9.3 Novel Opioid Molecules

11.10 Cannabinoids and Pain

12. Research Interviews from Our Survey

12.1 Interview with Dr Bradley S. Galer, MD, President of Pain Group, Nuvo Research Inc.

12.1.1 Perspective on the Pain Treatment Market

12.1.2 Challenges in the Pain Treatment Market

12.1.3 Insight on the Topical Pain Relief Market

12.1.4 Thoughts on Arthritic Pain Market Developments

12.1.5 Thoughts on Key Submarkets

12.1.6 Views on Drivers and Threats

12.1.7 Treatments in the R&D Pipeline

12.1.8 Future of World Pain Treatment Market

12.2 Interview with Dr John Andrews, President and Chief Scientific Officer, NeurAxon.

12.2.1 Perspective on the Pain Treatment Market

12.2.2 Key Unmet Needs

12.2.3 Thoughts on Key Submarkets

12.2.4 Development of the Anti-Migraine Drug Market

12.2.5 Views on Drivers and Threats

12.2.6 Thoughts on National Market Opportunities

12.2.7 Treatments in the R&D Pipeline

12.2.8 Views on the Future of the Market

13. Conclusions

13.1 The Pain Drug Market Will Achieve Revenue Growth from 2012

13.2 Narcotics Submarket Will Grow Despite Reported Concerns

13.3 Strong Growth Expected in Neuropathic and Cancer Pain Submarkets

13.4 Botox Approval Expected to Boost Anti-Migraine Submarket

13.5 The Anti-Arthritic Pain Drug Submarket Will Remain Strong

13.6 Leading National Markets Will Achieve Revenue Growth

13.7 The Worldwide Pain Drug Market Holds Strong Potential from 2012 to 2022

List of Tables

Table 2.1 Defining Acute and Chronic Pain

Table 3.1 World Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 3.2 World Pain Relieving Drug Sales Forecasts ($m), AGRs (%), CAGRs (%) for Submarkets, 2011-2017

Table 3.3 World Pain Relieving Drug Sales Forecasts ($m), AGRs (%), CAGRs (%) for Submarkets, 2018-2022

Table 3.4 World Pain Relieving Drug Market Shares (%) in Submarkets, 2011, 2017 & 2022

Table 4.1 World Narcotic Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 4.2 World Narcotic Pain Relieving Drug Sales Forecasts ($m), AGRs (%), CAGRs (%) for Leading Products, 2011-2017

Table 4.3 World Narcotic Pain Relieving Drug Sales Forecasts ($m), AGRs (%), CAGRs (%) for Leading Products, 2018-2022

Table 4.4 World Narcotic Pain Relieving Drug Market Shares (%), 2011, 2017 & 2022

Table 4.5 World Oxycontin ER Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 4.6 World Duragesic Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 4.7 World Opana ER Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 4.8 World Ultram ER Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 4.9 World Other Narcotic Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 5.1 World Non-Narcotic Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 5.2 World Non-Narcotic Pain Relieving Drug Sales Forecasts ($m), AGRs (%), CAGRs (%) for Leading Products, 2011-2017

Table 5.3 Non-Narcotic Pain Relieving Drugs Sales Forecasts ($m), AGRs (%), CAGRs (%) for Leading Products, 2018-2022

Table 5.4 World Non-Narcotic Pain Relieving Drug Market Shares (%), 2011, 2017 & 2022

Table 5.5 Advil North American Formulations, 2012

Table 5.6 World Advil Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 5.7 Panadol Formulations, 2012

Table 5.8 World Panadol Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 5.9 World Bayer Aspirin Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 5.10 World Efferalgan Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 5.11 Tylenol Products, 2012

Table 5.12 World Tylenol Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 5.13 World Other Non-Narcotic Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 6.1 Key Drugs Indicated for Neuropathic Pain, 2012

Table 6.2 FDA-Approved Drugs Indicated for Neuropathic Pain, 2012

Table 6.3 World Neuropathic Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 6.4 Rising Prevalence of Diabetes, 2011, 2030 & 2050 

Table 6.5 World Neuropathic Pain Relieving Drug Sales Forecasts ($m), AGRs (%), CAGRs (%), 2011-2022

Table 6.6 World Neuropathic Pain Relieving Drug Market Shares (%), 2011, 2017 & 2022

Table 6.7 World Lyrica Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 6.8 World Cymbalta Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 6.9 World Lidoderm Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 6.10 World Neurontin Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 6.11 World Nucynta ER Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 7.1 World Anti-Migraine Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 7.2 World Anti-Migraine Drug Sales Forecasts ($m), AGRs (%), CAGRs (%), 2011-2022

Table 7.3 World Anti-Migraine Drug Market Shares (%), 2011, 2017 & 2022

Table 7.4 World Maxalt Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 7.5 World Zomig Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 7.6 World Relpax Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 7.7 World Imitrex/Imigran Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 7.8 World Botox Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 7.9 World Axert Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 7.10 World Treximet Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 8.1 Examples of Anti-Arthritic Pain Drugs, 2012

Table 8.2 World Anti-Arthritic Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 8.3 World Anti-Arthritic Drug Market Shares (%), 2011, 2017 & 2022

Table 8.4 World Anti-Arthritic Drug Sales Forecasts ($m), AGRs (%), CAGRs (%), 2011-2022

Table 8.5 World Humira Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 8.6 World Enbrel Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 8.7 World Remicade Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 8.8 World Rituxan Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 8.9 World Celebrex Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 8.10 World Voltaren Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 8.11 World Arcoxia Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 9.1 SWOT Analysis of the Pain Relieving Drug Market, 2012-2022

Table 9.2 World Population Forecast, 2012-2022

Table 10.1 Pain Relieving Drug Sales Forecasts ($m), AGRs (%), CAGRs (%) for Leading National Markets, 2011-2017

Table 10.2 Pain Relieving Drug Sales Forecasts ($m), AGRs (%), CAGRs (%) for Leading National Markets, 2018-2022

Table 10.3 Pain Relieving Drug Market Shares (%) in Leading National Markets, 2011, 2017 & 2022

Table 10.4 US: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 10.5 Japan: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 10.6 Germany: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 10.7 France: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 10.8 UK: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 10.9 Italy: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 10.10 Spain: Pain Relieving Drugs Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 10.11 China: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 10.12 India: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 10.13 Rest of the World: Pain Relieving Drug Sales Forecast ($m), AGRs (%), CAGRs (%), 2011-2022

Table 11.1 R&D Pipeline for Narcotic Pain Drugs, 2012

Table 11.2 R&D Pipeline for Non-Narcotic Pain Drugs, 2012

Table 11.3 R&D Pipeline for Neuropathic Pain Drugs, 2012

Table 11.4 R&D Pipeline for Anti-Migraine Pain Drugs, 2012

Table 11.5 R&D Pipeline for Anti-Arthritic Pain Drugs, 2012

List of Figures

Figure 2.1 Pain Categories

Figure 3.1 World Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 3.2 World Pain Relieving Drug Market Shares (%) of Submarkets, 2011

Figure 3.3 World Pain Relieving Drug Market Shares (%) of Submarkets, 2017

Figure 3.4 World Pain Relieving Drug Market Shares (%) of Submarkets, 2022

Figure 4.1 World Narcotic Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 4.2 World Narcotic Pain Relieving Drug Market Shares (%), 2011

Figure 4.3 World Narcotic Pain Relieving Drug Market Shares (%), 2017

Figure 4.4 World Narcotic Pain Relieving Drug Market Shares (%), 2022

Figure 4.5 World Oxycontin ER Sales Forecast ($m), 2011-2022

Figure 4.6 World Duragesic Sales Forecast ($m), 2011-2022

Figure 4.7 World Opana ER Sales Forecast ($m), 2011-2022

Figure 4.8 World Ultram ER Sales Forecast ($m), 2011-2022

Figure 4.9 World Other Narcotic Drug Sales Forecast ($m), 2011-2022

Figure 5.1 World Non-Narcotic Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 5.2 World Non-Narcotic Pain Relieving Drug Market Shares (%), 2011

Figure 5.3 World Non-Narcotic Pain Relieving Drug Market Shares (%), 2017

Figure 5.4 World Non-Narcotic Pain Relieving Drug Market Shares (%), 2022

Figure 5.5 World Advil Sales Forecast ($m), 2011-2022

Figure 5.6 World Panadol Sales Forecast ($m), 2011-2022

Figure 5.7 World Bayer Aspirin Sales Forecast ($m), 2011-2022

Figure 5.8 World Efferalgan Sales Forecast ($m), 2011-2022

Figure 5.9 World Tylenol Sales Forecast ($m), 2011-2022

Figure 5.10 World Other Non-Narcotic Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 6.1 World Neuropathic Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 6.2 Rising Prevalence of Diabetes, 2011, 2030 & 2050 

Figure 6.3 World Neuropathic Pain Relieving Drug Market Shares (%), 2011

Figure 6.4 World Neuropathic Pain Relieving Drug Market Shares (%), 2017

Figure 6.5 World Neuropathic Pain Relieving Drug Market Shares (%), 2022

Figure 6.6 World Lyrica Sales Forecast ($m), 2011-2022

Figure 6.7 World Cymbalta Sales Forecast ($m), 2011-2022

Figure 6.8 World Lidoderm Sales Forecast ($m), 2011-2022

Figure 6.9 World Neurontin Sales Forecast ($m), 2011-2022

Figure 6.10 World Nucynta ER Sales Forecast ($m), 2011-2022

Figure 7.1 World Anti-Migraine Drug Sales Forecast ($m), 2011-2022

Figure 7.2 World Anti-Migraine Drug Market Shares (%), 2011

Figure 7.3 World Anti-Migraine Drug Market Shares (%), 2017

Figure 7.4 World Anti-Migraine Drug Market Shares (%), 2022

Figure 7.5 World Maxalt Sales Forecast ($m), 2011-2022

Figure 7.6 World Zomig Sales Forecast ($m), 2011-2022

Figure 7.7 World Relpax Sales Forecast ($m), 2011-2022

Figure 7.8 World Imitrex/Imigran Sales Forecast ($m), 2011-2022

Figure 7.9 World Botox Sales Forecast ($m), 2011-2022

Figure 7.10 World Axert Sales Forecast ($m), 2011-2022

Figure 7.11 World Treximet Sales Forecast ($m), 2011-2022

Figure 8.1 World Anti-Arthritic Drug Sales Forecast ($m), 2011-2022

Figure 8.2 World Anti-Arthritic Drug Market Shares (%), 2011

Figure 8.3 World Anti-Arthritic Drug Market Shares (%), 2017

Figure 8.4 World Anti-Arthritic Drug Market Shares (%), 2022

Figure 8.5 World Humira Sales Forecast ($m), 2011-2022

Figure 8.6 World Enbrel Sales Forecast ($m), 2011-2022

Figure 8.7 World Remicade Sales Forecast ($m), 2011-2022

Figure 8.8 World Rituxan Sales Forecast ($m), 2011-2022

Figure 8.9 World Celebrex Sales Forecast ($m), 2011-2022

Figure 8.10 World Voltaren Sales Forecast ($m), 2011-2022

Figure 8.11 World Arcoxia Sales Forecast ($m), 2011-2022

Figure 9.1 World Population Forecast, 2012-2022

Figure 9.2 World Population Aged 65 or Over: Forecast, 2012-2022

Figure 9.3 Population Aged 65 and Over in Seven Leading Developed Pain Drug Markets, 2011 & 2022

Figure 10.1 US, Japan & Rest of World: Pain Relieving Drug Sales Forecasts ($m), 2011-2022

Figure 10.2 Leading European and Emerging Asian Markets: Pain Relieving Drug Sales Forecasts ($m), 2011-2022

Figure 10.3 Pain Relieving Drug Market Shares (%) in Leading National Markets, 2011

Figure 10.4 Pain Relieving Drug Market Shares (%) in Leading National Markets, 2017

Figure 10.5 Pain Relieving Drug Market Shares (%) in Leading National Markets, 2022

Figure 10.6 US: Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 10.7 Japan: Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 10.8 Germany: Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 10.9 France: Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 10.10 UK: Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 10.11 Italy: Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 10.12 Spain: Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 10.13 China: Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 10.14 India: Pain Relieving Drug Sales Forecast ($m), 2011-2022

Figure 10.15 Rest of the World: Pain Relieving Drug Sales Forecast ($m), 2011-2022 

Companies Listed

AB Science

Abbott Laboratories

AcelRx Pharmaceuticals 

Actavis

Acura Pharmaceuticals 

Allergan

Almirall

Alpharma

ALZA Corporation

American Council for Headache Education

Amgen

Anesiva

Aoxing Pharmaceuticals

Apotec

Apotex

Arcion Therapeutics

Astellas Pharma

AstraZeneca

Avanir Pharmaceuticals

Bayer

BioDelivery Sciences 

Biogen Idec

Biovail Corporation

Bristol-Myers Squibb 

Britannia Pharmaceuticals

CeNeS Pharmaceuticals 

Centocor Ortho Biotech 

China Aoxing

CK Life Sciences

Collegium Pharmaceutical

CoLucid Pharmaceuticals

Dainippon

Dara Biosciences

Depomed

Descartes Therapeutics

Dr. Reddy's Laboratories

Durect

Eisai

Eli Lilly

Endo Pharmaceuticals

EpiCept

European Medicines Agency (EMA)

Food and Drug Administration (FDA)

Forest Pharmaceuticals 

Galderma

Genentech

Genmab

GlaxoSmithKline (GSK) 

Grünenthal

Horizon Pharma

Human Genome Sciences

Insys Therapeutics

International Association for the Study of Pain (IASP)

Ipsen

IVAX Pharmaceuticals

Janssen Pharmaceuticals

Johns Hopkins University

Johnson and Johnson (J&J)

King Pharmaceuticals

Ligand Pharmaceuticals

Lundbeck

MAP Pharmaceuticals

Merck & Co.

Merck Serono 

Mitsubishi Tanabe Pharma

Mylan

National Health Service (NHS)

National Institute for Health and Clinical Excellence (NICE)

Nektar Therapeutics

NeurAxon

NeurogesX

Neurotune

Newron Pharmaceuticals

NicOx Pharmaceuticals

Novartis

NuPathe

Nuvo Research

Omeros

Ono Pharmaceutical 

Organon

Ortho-McNeil

Pacira Pharmaceuticals

Pain Therapeutics

Paion

Par Pharmaceuticals 

Penwest

Pfizer

Pharmacia

PLx Pharma

Pozen

PriCara Pharmaceuticals 

Procter & Gamble

Proteus

Purdue Pharma

QRxPharma

Ranbaxy

Ratiopharm

Rigel Pharmaceuticals 

Roche

Schering Plough

Shire

SkyePharma

Solvay Pharmaceuticals 

Spinifex Pharmaceuticals

Stada Pharmaceuticals

Sun Pharmaceuticals

Syntaxin

Takeda

Teikoku

Teva Pharmaceutical Industries

The Arthritis Foundation 

The International Diabetes Federation (IDF)

The Neuropathy Association

The World Health Organization (WHO) 

UCB

University of Queensland

US Census Bureau 

US Society for Neuroscience

US WorldMeds

Valeant Pharmaceuticals International

Watson Pharmaceuticals

WEX Pharmaceuticals 

Wyeth (now part of Pfizer) 

Xenoport 

Zars Pharmaceuticals

Zenyaku Kogyo

Zogenix 

To order this report:

Drug_and_Medication Industry: World Pain Relieving Drug Market 2012-2022

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com

US: (805)-652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker